Shots:

• Mundipharma acquires all shares of the parent company of Cinfa- Infarco including Pelmeg (pegfilgrastim- biosimilar) having global market value $4.5B
• The acquisition focuses on expansion of biosimilar platform by developing multiple biosimilars indicated across various therapy areas
• Pelmeg is a granulocyte-colony stimulating factor (GCSF) used for the treatment of CT-induced neutropenia and also received CHMP approval on 20^th Sep- 2018

Ref: Mundipharma | Image: Pro Biosimilars